Evidence map›Paper›PMID 30042655›Full record

ReviewFrontiers in neuroscience2018

Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration.

Moataz Abdalkader, Riikka Lampinen, Katja M Kanninen, Tarja M Malm, Jeffrey R Liddell

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 215 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
215citing papers in PubMed, 2 pooled it
27.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

215 citing papers in PubMed, 2 syntheses or guidelines pooled it, 421 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Ironing out mechanisms of ferroptotic death to tailor new stroke therapies.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Review
  12. Non-canonical cell death in neurodegeneration: emerging mechanisms and therapeutic Frontiers.Apoptosis : an international journal on programmed cell death · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Schisanhenol Inhibits MPTP/MPPNeurochemical research · 2025
    Article
  18. Article
  19. Article
  20. Review

155 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Moataz AbdalkaderA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Riikka LampinenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Katja M KanninenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Tarja M MalmA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Jeffrey R LiddellDepartment of Pharmacology and Therapeutics, The University of Melbourne, Parkville, VIC, Australia.
University of Eastern Finland · FIUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a newly described form of regulated cell death, distinct from apoptosis, necroptosis and other forms of cell death. Ferroptosis is induced by disruption of glutathione synthesis or inhibition of glutathione peroxidase 4, exacerbated by iron, and prevented by radical scavengers such as ferrostatin-1, liproxstatin-1, and endogenous vitamin E. Ferroptosis terminates with mitochondrial dysfunction and toxic lipid peroxidation. Although conclusive identification of ferroptosis

Indexed as

Alzheimer’s diseaseerastinHuntington’s diseaseKeap1motor neuron diseaseParkinson’s diseaseRSL3system xc-

Identifiers

PMID30042655
PMCPMC6048292
OpenAlexW2876414845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.